COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment
JMIR Public Health and Surveillance · 2024
DOI: 10.2196/57242 ↗At a glance
Journal article in JMIR Public Health and Surveillance, 2024. Written by David Salisbury and 8 co-authors. Institution: Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, United Kingdom. Major MEDLINE topics: COVID-19 Vaccines, Choice Behavior, COVID-19. Cited 5 times so far (Crossref); 37 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Despite strong evidence supporting COVID-19 vaccine efficacy and safety, a proportion of the population remains hesitant to receive immunization. Discrete choice experiments (DCEs) can help assess preferences and decision-making drivers.
Objective
We aim to (1) elicit preferences for COVID-19 vaccines in Canada, Germany, the United Kingdom, and the United States; (2) understand which vaccine attributes people there value; and (3) gain insight into the choices that different population subgroups make regarding COVID-19 vaccines.
Methods
Participants in the 2019nCoV-408 study were aged ≥18 years; self-reported antivaccinationists were excluded. A DCE with a series of 2 hypothetical vaccine options was embedded into a survey to determine participant treatment preferences (primary objective). Survey questions covered vaccine preference, previous COVID-19 experiences, and demographics, which were summarized using descriptive statistics to understand the study participants’ backgrounds. In the DCE, participants were provided choice pairs: 1 set with and 1 without an “opt-out” option. Each participant viewed 11 unique vaccine profiles. Vaccine attributes consisted of type (messenger RNA or protein), level of protection against any or severe COVID-19, risk of side effects (common and serious), and potential coadministration of COVID-19 and influenza vaccines. Attribute level selections were included for protection and safety (degree of effectiveness and side effect risk, respectively). Participants were stratified by vaccination status (unvaccinated, or partially or fully vaccinated) and disease risk group (high-risk or non–high-risk). A conditional logit model was used to analyze DCE data to estimate preferences of vaccine attributes, with the percentage relative importance calculated to allow for its ranking. Each model was run twice to account for sets with and without the opt-out options.
Results
The mean age of participants (N=2000) was 48 (SD 18.8) years, and 51.25% (1025/2000) were male. The DCE revealed that the most important COVID-19 vaccine attributes were protection against severe COVID-19 or any severity of COVID-19 and common side effects. Protection against severe COVID-19 was the most important attribute for fully vaccinated participants, which significantly differed from the unvaccinated or partially vaccinated subgroup (relative importance 34.8% vs 30.6%; P=.049). Avoiding serious vaccine side effects was a significantly higher priority for the unvaccinated or partially versus fully vaccinated subgroup (relative importance 10.7% vs 8.2%; P=.044). Attributes with significant differences in the relative importance between the high-risk versus non–high-risk subgroups were protection against severe COVID-19 (38.2% vs 31.5%; P
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, United Kingdom.
- Graduate School of Public Health and Health Policy (CUNY SPH), City University of New York, New York, NY, United States.
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.
- School of Pharmacy, University of Waterloo, Ontario, ON, Canada.
- Department of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
- ICON Insights, Evidence and Value-Patient Centered Outcomes, Reading, United Kingdom.
ORCID profiles: David Salisbury, Jeffrey V Lazarus, Nancy Waite, Clara Lehmann, Sumitra Sri Bhashyam, Marie de la Cruz, Beth Hahn, Matthew D Rousculp, Paolo Bonanni
Cite
APA
Salisbury, D., Lazarus, J. V., Waite, N., Lehmann, C., Sri Bhashyam, S., de la Cruz, M., Hahn, B., Rousculp, M. D., & Bonanni, P. (2024). COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment. JMIR Public Health and Surveillance. https://doi.org/10.2196/57242
Vancouver
Salisbury D, Lazarus JV, Waite N, Lehmann C, Sri Bhashyam S, de la Cruz M, et al. COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment. JMIR Public Health and Surveillance. 2024. doi:10.2196/57242
BibTeX
@article{Salisbury2024,
author = {Salisbury, David and Lazarus, Jeffrey V and Waite, Nancy and Lehmann, Clara and Sri Bhashyam, Sumitra and de la Cruz, Marie and Hahn, Beth and Rousculp, Matthew D and Bonanni, Paolo},
title = {COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment},
journal = {JMIR Public Health and Surveillance},
year = {2024},
doi = {10.2196/57242}
}
EUVIMED